Dianthus Therapeutics
DNTH
72 hedge funds and large institutions have $65.8M invested in Dianthus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 9 closing their positions.
32% more capital inflows, than outflows
Capital inflows: $8.62M | Capital outflows: $6.54M
1.72% more ownership
Funds ownership: 77.41% → 79.13% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 75 → 72 (-3)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
29% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$6.14M |
| 2 |
Woodline Partners
San Francisco,
California
|
+$636K |
| 3 |
Janus Henderson Group
London,
|
+$522K |
| 4 |
Millennium Management
New York
|
+$376K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$193K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Casdin Capital
New York
|
-$3.58M |
| 2 |
JP Morgan Chase
New York
|
-$787K |
| 3 |
Renaissance Technologies
New York
|
-$559K |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$258K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$227K |
DNTH Hedge Fund Activity: Q3 2022 in Review
72 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2022, worth a combined $65.8M — up 20% from $54.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of DNTH and 8 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 17 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $6.14M. The largest seller was Casdin Capital, cutting an estimated $3.58M.
- 72 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2022, down from 75 in Q2 2022.
- Funds reported $65.8M of Dianthus Therapeutics stock for Q3 2022, up 20% quarter-over-quarter.
- 8 funds opened new Dianthus Therapeutics positions in Q3 2022 and 9 closed out, a net change of -1 holder.
- The largest Dianthus Therapeutics buyer in Q3 2022 was RA Capital Management, an estimated $6.14M added.
- The largest Dianthus Therapeutics seller in Q3 2022 was Casdin Capital, an estimated $3.58M sold.
Based on aggregated 13F filings for Q3 2022.